Zobrazeno 31 - 40
of 785
pro vyhledávání: ''
Autor:
Vanessa Davies, Ioannis A. Voutsadakis
Publikováno v:
Cancer Investigation. 38:94-101
Background: Amplification of the centromeric region of chromosome 17 (CEP17) as measured by In Situ Hybridization (ISH) of the CEP17 probe is used clinically as part of the ISH assay for HER2 statu...
Publikováno v:
Cancer Investigation. 38:13-22
Objective: Cancer stem cells are self-renewal cells in tumors and can produce heterogeneous tumor cells, which play an important role in the development of lung squamous cell carcinoma (LSCC). In o...
Autor:
Sayumi Yoshida, Machi Suka, Masato Okamoto, Masayuki Saruta, Tadashi Akiba, Shin Kan, Hiroaki Kitamura, Shuichi Fujioka, Shigeo Koido, Takafumi Akasu, Takeyuki Misawa, Zensho Ito, Haruo Sugiyama, Hiroyuki Yanagisawa, Tsuuse Bito
Publikováno v:
Cancer Investigation. 37:463-477
The associations of the immunological status of the pancreatic ductal adenocarcinoma (PDA) microenvironment with prognosis were assessed. A high tumor-infiltrating lymphocyte (TIL) density was associated with a better prognosis. Importantly, even wit
Autor:
Eric H. Bernicker, Bin S. Teh, Jun Zhang, E. Brian Butler, Shraddha M. Dalwadi, Andrew M. Farach
Publikováno v:
Cancer Investigation. 37:506-511
With modern radiotherapy, stage I non-small cell lung cancer (S1NSCLC) cure is extended to nonsurgical candidates. Despite this, some S1NSCLC remains untreated. We aim to identify factors associated with no treatment. 62,213 S1NSCLC cases were identi
Publikováno v:
Cancer Investigation. 37:387-392
Purpose: Desmoid tumors are locally aggressive nonmalignant soft tissue tumors, which frequently recur after therapy. The optimal treatment is still controversial because of the lack of large resea...
Autor:
Rebecca M. Schwartz, Emanuela Taioli, Kristin Bevilacqua, Bian Liu, Katherine A. Ornstein, Naomi Alpert
Publikováno v:
Cancer Investigation. 37:299-310
Age-related decreases in Quality of Life (QoL) are often compounded by comorbidities, including cancer. This study aimed to examine QoL changes before and after a new cancer diagnosis using data from the National Health and Aging Trend Study (NHATS),
Autor:
Kelsey Maguire, Andriy Derkach, Nandini Umesh Yadav, Jeffrey S. Groeger, Petros Grivas, Ali Raza Khaki, Adam Klotz, Margaret M. Madeleine, Esther Babady, Lisa Tachiki, Sandy Simcha Nath, Afia Babar, Gary H. Lyman, Ying Taur, Justin Jee, Sanjay Chawla, Molly Maloy, Rocio Perez-Johnston, Daniel J. Henning, H. Laura Aaltonen
Publikováno v:
Cancer investigation. 40(1)
Our goal was to identify discrete clinical characteristics associated with safe discharge from an emergency department/urgent care for patients with a history of cancer and concurrent COVID-19 infection during the SARS-CoV-2 pandemic and prior to wid
Autor:
Mansoureh Dehghani, Pejman Porouhan, Mona Ariamanesh, Farbod Hatami, Somayeh Ashkar Tizabi, Gary H. Lyman, Babak PeyroShabany, James S Welsh, Seyed Alireza Javadinia, Maryam Nabavifard, Danial Fazilat-Panah, Ahmad Ghasemi
Publikováno v:
Cancer investigation. 40(2)
Patients with cancer are at significantly greater risk of COVID-19 and its complications than the general population. Since IgG antibodies remain detectable well after infection with the SARS-CoV-2 virus, seroprevalence can be used to estimate the pr
Publikováno v:
Cancer investigation. 40(3)
BACKGROUND Pain is a common symptom in cancer patients. Hypnosis is considered one of the most recognized non-pharmacological techniques in pain management. In oncology, this technique can be used as a complementary treatment to reduce the level of p
Autor:
Takafumi Yamamoto, Tetsunari Hase, Hiroki Kawashima, Masatoshi Ishigami, Takanori Ito, Naoyuki Yogo, Naozumi Hashimoto, Takashi Abe, Kenta Yamamoto, Takashi Honda, Takahiro Hatta, Norihiro Imai, Satoshi Yasuda, Hidenori Toyoda, Hirofumi Shibata, Mitsuhiro Fujishiro, Kazuyuki Mizuno, Yoji Ishizu
Publikováno v:
Cancer investigation. 40(2)
It remains unclear whether severe liver immune-related adverse events (liver-irAEs) can affect the prognosis in non-small cell lung carcinoma (NSCLC) patients. Of the 365 NSCLC patients treated with immune checkpoint inhibitors (ICIs), 19 suffered fr